Published in Blood Weekly, November 14th, 2002
"Screening for galactomannan (GM) has been adopted by many European centers as part of the management plan for allogeneic stem cell transplant recipients," according to Johan Maertens and colleagues at Gasthuisberg University Hospital in Leuven. "However, the temporal onset of GM antigenemia remains unknown."
Maertens and coauthors found that GM antigenemia rose to detectable levels more than a week before other signs of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.